• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Structure Therapeutics Inc.

    11/14/24 10:26:11 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GPCR alert in real time by email
    SC 13G 1 Structure093024.txt JANUS NEW UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 0* Name of Issuer: STRUCTURE THERAPEUTICS INC Title of Class of Securities: American Depositary Shares CUSIP Number: 86366E106 Date of Event Which Requires Filing of this Statement: 9/30/2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed. [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No.: 86366E106 1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Janus Henderson Group plc EIN #00-0000000 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP a. ___ b. ___ 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Jersey, Channel Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5. SOLE VOTING POWER 0** 6. SHARED VOTING POWER 3,956,878** 7. SOLE DISPOSITIVE POWER 0** 8. SHARED DISPOSITIVE POWER 3,956,878** 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,956,878** 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES Not applicable 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.9%** 12. TYPE OF REPORTING PERSON IA, HC ** See Item 4 of this filing Item 1. (a). Name of Issuer: STRUCTURE THERAPEUTICS INC ("Structure") (b). Address of Issuer's Principal Executive Offices: 611 GATEWAY BLVD SUITE 223 SOUTH SAN FRANCISCO, CA 94080 Item 2. (a).-(c). Name, Principal Business Address, and Citizenship of Persons Filing: (1) Janus Henderson Group plc 201 Bishopsgate EC2M 3AE, United Kingdom Citizenship: Jersey, Channel Islands (d). Title of Class of Securities: American Depositary Shares (e). CUSIP Number: 86366E106 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) and the person filing, Janus Henderson Group plc ("Janus Henderson") is a parent holding company/control person in accordance with Section 240.13d-1(b)(ii)(G). See Item 4 for additional information. Item 4. Ownership The information in items 1 and 5 through 11 on the cover page(s) on Schedule 13G is hereby incorporated by reference. Janus Henderson has a 100% ownership stake in Janus Henderson Investors U.S. LLC ("JHIUS"), Janus Henderson Investors UK Limited ("JHIUKL") and Janus Henderson Investors Australia Institutional Funds Management Limited ("JHIAIFML"), (each an "Asset Manager" and collectively as the "Asset Managers"). Due to the above ownership structure, holdings for the Asset Managers are aggregated for purposes of this filing. Each Asset Manager is an investment adviser registered or authorized in its relevant jurisdiction and each furnishing investment advice to various fund, individual and/or institutional clients (collectively referred to herein as "Managed Portfolios"). As a result of its role as investment adviser or sub-adviser to the Managed Portfolios, JHIUS may be deemed to be the beneficial owner of 3,911,114 shares or 6.8% of the shares outstanding of Structure American Depositary Shares held by such Managed Portfolios. However, JHIUS does not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaims any ownership associated with such rights. Item 5. Ownership of Five Percent or Less of a Class Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person The Managed Portfolios, set forth in Item 4 above, have the right to receive all dividends from, and the proceeds from the sale of, the securities held in their respective accounts. The interest of any one such Managed Portfolio does not exceed 5% of the class of securities. These shares were acquired in the ordinary course of business, and not with the purpose of changing or influencing control of the Issuer. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company JHIUS, JHIUKL and JHIAIFML are indirect subsidiaries of Janus Henderson and are registered investment advisers furnishing investment advice to Managed Portfolios. Item 8. Identification and Classification of Members of the Group Not applicable. Item 9. Notice of Dissolution of Group Not applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect. SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. JANUS HENDERSON GROUP PLC By /s/ Kristin Mariani Kristin Mariani, Head of North America Compliance, CCO Date 11/14/2024 Name/Title Attorney-In-Fact The original statement shall be signed by each person on whose behalf the statement is filed or his or her authorized representative. If the statement is signed on behalf of a person by his or her authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement (see Exhibit A), provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his or her signature. EXHIBIT A POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary
    Get the next $GPCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GPCR

    DatePrice TargetRatingAnalyst
    5/2/2025$60.00Buy
    Citigroup
    2/28/2025Outperform
    William Blair
    1/8/2025$50.00Buy
    Stifel
    12/4/2024$80.00Buy
    H.C. Wainwright
    9/23/2024$118.00Overweight
    Morgan Stanley
    5/21/2024$65.00Overweight
    JP Morgan
    4/9/2024$65.00Overweight
    Cantor Fitzgerald
    10/19/2023$90.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $GPCR
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Structure Therapeutics Inc.

      SCHEDULE 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

      5/15/25 8:42:28 AM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Structure Therapeutics Inc.

      SCHEDULE 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

      5/14/25 12:32:44 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Structure Therapeutics Inc.

      SCHEDULE 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

      5/13/25 11:32:29 AM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GPCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

      SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

      11/14/24 5:46:12 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Structure Therapeutics Inc.

      SC 13G - Structure Therapeutics Inc. (0001888886) (Subject)

      11/14/24 10:26:11 AM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

      SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

      11/14/24 9:33:27 AM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GPCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

      SAN FRANCISCO, May 29, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences in June. Jefferies Global Healthcare Conference Format: Fireside chat and 1x1 meetingsDate/time: Thursday, June 5 at 8:10 a.m. ETLocation: New York, NY Goldman Sachs Global Healthcare Conference Format: Fireside chat and 1x1 meetingsDate/time: Wednesday, June 11 at 10:40 a.m. ETLocation: Miami, FL The live and archived webcasts of the fireside chats will be accessible from the compa

      5/29/25 4:05:00 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights

      Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Investigational New Drug (IND)-enabling activities underway; First-in-human Phase 1 initiation anticipated by year-end 2025 Strong year-end financial position with cash, cash equivalent and short-term investments of $883.5 million SAN FRANCISCO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today reported financial results for the fourth quarter and f

      2/27/25 4:05:00 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

      SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March. Guggenheim SMID Cap Biotech Conference  Format:Fireside chat and 1x1 meetings Date/time:Wednesday, February 5 at 10:30 a.m. ET Location:New York, NY Webcast link:https://wsw.com/webcast/guggen2/gpcr/2003892    Leerink Global Healthcare Conference  Format:Fireside chat and 1x1 meetings Date/time:Monday, March 10 at 1:00 p.m. ET 

      1/30/25 8:30:00 AM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GPCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Structure Therapeutics with a new price target

      Citigroup initiated coverage of Structure Therapeutics with a rating of Buy and set a new price target of $60.00

      5/2/25 8:15:19 AM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • William Blair initiated coverage on Structure Therapeutics

      William Blair initiated coverage of Structure Therapeutics with a rating of Outperform

      2/28/25 7:24:16 AM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Structure Therapeutics with a new price target

      Stifel initiated coverage of Structure Therapeutics with a rating of Buy and set a new price target of $50.00

      1/8/25 7:51:31 AM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GPCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer

      SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase of development and operational success. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D. as part of a planned succession, effective September 18. Dr. Coll has served as Vice President of Clinical Development at Structure since 2022, leading the GSBR-1290 program, Structure's oral small molecule GLP-1 agonist that is planned to enter Phase

      9/17/24 4:05:00 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Structure Therapeutics Appoints Angus C. Russell to Board of Directors

      SAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the appointment of Angus C. Russell to its board of directors. Mr. Russell previously served as Chief Executive Officer of Shire plc and brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry. "Structure is at an important moment in its evolution as we prepare to advance our oral small molecule GLP-1 agonist, GSBR-1290, into late-stage clinical development for obesity," said Raymond Steve

      8/27/24 4:05:00 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

      Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study of GSBR-1290 expected in latter half of fourth quarter 2023 SAN FRANCISCO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the second quarter June 30, 2023, and highlighted recent corporate achievements. "We have continued our momentum and are on track to report topline data from our fully-enrolled Phase 2a study of GSBR-129

      8/10/23 4:05:00 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GPCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Development Officer Hall Ashley was granted 51,048 units of Ordinary Shares, increasing direct ownership by 76% to 118,338 units (SEC Form 4)

      4 - Structure Therapeutics Inc. (0001888886) (Issuer)

      3/18/25 8:45:14 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF TECHNOLOGY OFFICER Ma Yingli was granted 63,810 units of Ordinary Shares, increasing direct ownership by 174% to 100,539 units (SEC Form 4)

      4 - Structure Therapeutics Inc. (0001888886) (Issuer)

      3/18/25 8:45:12 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Coll Crespo Blas was granted 116,988 units of Ordinary Shares, increasing direct ownership by 114% to 219,588 units (SEC Form 4)

      4 - Structure Therapeutics Inc. (0001888886) (Issuer)

      3/18/25 8:45:17 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GPCR
    Financials

    Live finance-specific insights

    See more
    • Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

      Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most advanced oral small molecule amylin-based drug candidate, with Phase 1 study initiation expected by year end 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671. Amy

      12/17/24 4:01:00 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

      First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial position with cash, cash equivalent and short-term investments of $915.3 million expected to fund projected operations and key clinical milestones through at least 2027 Conference Call to discuss GSBR-1290 ACCESS development program today at 4:30 p.m. ET SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today

      11/13/24 4:05:00 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

      Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher doses of GSBR-1290 over 36 weeks; first patient expected to be dosed by end of 2024 Topline data from both ACCESS and ACCESS II studies expected in the fourth quarter of 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the first pati

      11/13/24 4:01:00 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care